Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 5/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | FHIT | P49789 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15439768 | 0.86 | CYP1A2 (0.72) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL12495269 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL12495068 | 0.82 | CYP2C19 (1.00) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL12495017 | 0.82 | SMN1; SMN2 (0.73) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL15444580 | 0.79 | CYP1A2 (0.64) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL12493967 | 0.78 | CYP1A2 (0.63) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL15444643 | 0.77 | SMN1; SMN2 (0.59) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL12494753 | 0.74 | CYP1A2 (0.64) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL12494749 | 0.74 | CYP1A2 (0.64) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL12495310 | 0.74 | CYP1A2 (0.64) | CYP1A2CYP2C19CYP2C9SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479771-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2019-11-19 | — | — | US | disclosed |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2018-02-01 | — | — | US | disclosed |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | CYP1A2 14/4885CYP2C19 11/4885CYP2C9 54/4885 |
| US-10479771-B2 | Pyridazinone and pyridone compounds | XDH, PNPO, PDXK | CYP1A2 14/4885CYP2C19 11/4885CYP2C9 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.